Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00220766 · ClinicalTrials.gov registry record · Phase 3
Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients
A Phase 3 study, sponsored by Grifols Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT00220766: Completed Phase 3 study, sponsored by Grifols Therapeutics.
NCT00220766 is a Phase 3 study that has completed, run by Grifols Therapeutics. The registered enrollment target is 100 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00220766, a Phase 3 study, has completed, sponsored by Grifols Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
The objective of this study is to determine if the safety and tolerability of Immune Globulin Intravenous (Human), 10% caprylate/chromatography (IGIV-C)purified is similar when infused at two different infusion rates. The primary objective is to compare the incidence and severity of all infusion related adverse events when IGIV-C, 10% is administered at a rate of 0.14 mL/kg/min compared to a rate of 0.08 mL/kg/min after a single daily infusion.
Interventions
- DRUG Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified
- DRUG Dextrose, 5% in Water
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2002-08 |
| Est. Completion | 2004-03 |
| Phase | Phase 3 |
What the finished NCT00220766 record still lists
NCT00220766 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified is the first listed.
NCT00220766 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00220766 about?
NCT00220766 is a clinical study titled "Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients". The objective of this study is to determine if the safety and tolerability of Immune Globulin Intravenous (Human), 10% caprylate/chromatography (IGIV-C)purified is similar when infused at two different infusion rates. The primary objective is to compare the incidence and severity of all infusion rel...
What is the current status of trial NCT00220766?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2002-08. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00220766?
The interventions under investigation include: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified (DRUG), Dextrose, 5% in Water (DRUG).
Who is sponsoring clinical trial NCT00220766?
This trial is sponsored by Grifols Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00220766's enrollment target sits among peer trials
100 1681st of 2000 higher than 288 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia